OncoMatch/Clinical Trials/NCT07677774

GPC3-Targeted PET/CT in Hepatocellular Carcinoma

Official title: Glypian-3 (GPC3)- Targeted PET Imaging in Hepatocellular Carcinoma

Is NCT07677774 recruiting? Yes, currently enrolling (Oct 2026). This NA trial studies non-drug interventions for hepatocellular carcinoma (hcc).

NARecruitingThe First Affiliated Hospital of Xiamen UniversityNCT07677774Data as of Oct 2026Location: China

The objective of the study is to evaluate the diagnostic value of GPC3-targeted PET/CT in patients with suspected or histologically/clinically confirmed hepatocellular carcinoma, and to compare with contrast-enhanced MRI.

Check if I qualify

Extracted eligibility criteria

Cancer type

Hepatocellular Carcinoma

Demographics

Ages ≤ 90

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Frequently asked questions

Is NCT07677774 currently recruiting?

Yes, this trial is currently recruiting patients.

Is there an age limit?

Yes. Patients must be 90 years or younger.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify

Hepatocellular Carcinoma trials